BIOLASE (BIOL) Receiving Somewhat Favorable Press Coverage, Study Shows

News articles about BIOLASE (NASDAQ:BIOL) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BIOLASE earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news headlines about the medical technology company an impact score of 46.6084811028332 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

BIOL remained flat at $$1.16 during trading on Friday. The company had a trading volume of 43,974 shares, compared to its average volume of 53,332. BIOLASE has a twelve month low of $1.14 and a twelve month high of $6.00. The company has a quick ratio of 1.54, a current ratio of 2.56 and a debt-to-equity ratio of 0.08.

BIOLASE (NASDAQ:BIOL) last released its quarterly earnings results on Wednesday, May 2nd. The medical technology company reported ($0.20) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.20). The business had revenue of $10.02 million during the quarter. BIOLASE had a negative return on equity of 66.34% and a negative net margin of 38.56%.

About BIOLASE

BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Insider Buying and Selling by Quarter for BIOLASE (NASDAQ:BIOL)

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply